In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent 'mischief' lurks after Myriad

This article was originally published in Clinica

Executive Summary

In declaring that isolated DNA is not patent eligible, but complementary DNA (cDNA) is, the US Supreme Court has left open the opportunity for mischief for further attempts to narrow or undermine the patentability of DNA genetic materials in a broader sense. That is the view of San Francisco lawyer Robert Sachs, a partner in the Intellectual Property Practice Group at Fenwick & West.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts